331 related articles for article (PubMed ID: 24382388)
1. Clinical development of demethylating agents in hematology.
Navada SC; Steinmann J; Lübbert M; Silverman LR
J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
[TBL] [Abstract][Full Text] [Related]
2. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
3. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
4. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
7. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
8. DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
Casellas Román HL; Venugopal K; Feng Y; Shabashvili DE; Posada LM; Li J; Guryanova OA
Leuk Res; 2020 Jul; 94():106372. PubMed ID: 32445940
[No Abstract] [Full Text] [Related]
9. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
10. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
[TBL] [Abstract][Full Text] [Related]
11. Review: recent clinical trials in epigenetic therapy.
Oki Y; Issa JP
Rev Recent Clin Trials; 2006 May; 1(2):169-82. PubMed ID: 18473969
[TBL] [Abstract][Full Text] [Related]
12. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
[TBL] [Abstract][Full Text] [Related]
13. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
14. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD
Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
Bryan J; Kantarjian H; Garcia-Manero G; Jabbour E
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):661-72. PubMed ID: 21500965
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
17. Decitabine in the treatment of myelodysplastic syndromes.
Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
[TBL] [Abstract][Full Text] [Related]
18. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213
[No Abstract] [Full Text] [Related]
19. Demethylating agents in myeloid malignancies.
Garcia-Manero G
Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
[TBL] [Abstract][Full Text] [Related]
20. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]